Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11956429 | 0.82 | SPHK1 (0.48) | SPHK1BRD4CTSKHCRTR2CHRM2 | |
| SCHEMBL25148798 | 0.82 | SPHK1 (0.48) | SPHK1BRD4CTSKHCRTR2CHRM2 | |
| SCHEMBL9752336 | 0.81 | SPHK1 (0.51) | SPHK1BRD4CTSKHCRTR2CHRM2 | |
| SCHEMBL14314018 | 0.81 | SPHK1 (0.54) | SPHK1BRD4CTSKHCRTR2CHRM2 | |
| SCHEMBL10272352 | 0.81 | SPHK1 (0.54) | SPHK1BRD4CTSKHCRTR2CHRM2 | |
| SCHEMBL10272353 | 0.81 | SPHK1 (0.54) | SPHK1BRD4CTSKHCRTR2CHRM2 | |
| SCHEMBL10223487 | 0.81 | SPHK1 (0.47) | SPHK1BRD4CTSKHCRTR2CHRM2 | |
| SCHEMBL6979603 | 0.78 | SPHK1 (0.49) | SPHK1BRD4CTSKHCRTR2CHRM2 | |
| SCHEMBL1833725 | 0.78 | SPHK1 (0.49) | SPHK1BRD4CTSKHCRTR2CHRM2 | |
| SCHEMBL1833726 | 0.78 | SPHK1 (0.49) | SPHK1BRD4CTSKHCRTR2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511039-B2 | β-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins | MYRIAD GENETICS, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-20060276408-A1 | Beta-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins | MYRIAD GENETICS, INCORPORATED (US) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276408-A1 | Beta-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins | SERPINB1, SERPINE1, SERPINA2 | SPHK1 2300/4885BRD4 2047/4885CTSK 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.